India vs. Global Medical Tourism: UAE’s Success with Indian Talent India’s medical tourism sector, valued at $7.69 billion in 2024 and attracting 700,000–800,000 patients annually, holds immense potential but underperforms due to systemic deficiencies. Despite offering treatments at 60–80% lower costs than Western countries and expertise in cardiac surgery, organ transplants, and oncology, India lags behind competitors like Thailand ($6–$7 billion, 1.8–2 million patients), Malaysia ($1.5–$2 billion, 1–1.2 million patients), Singapore ($2.2–$2.5 billion, 500,000 patients), Turkey ($2.5–$3 billion, 1–1.5 million patients), and the UAE ($3.5–$5 billion, 500,000–700,000 patients). Indian-managed facilities in the UAE, such as Aster DM Healthcare and Zulekha, capture 20–30% of its market, leveraging Indian expertise in a superior ecosystem. India’s growth is hindered by fragmented policies, poor infrastructure, weak branding, and reliance on volatile regions. China’s nascent sector (<$...